28:23

Key Insights: Lymphoma & Myeloma 2017 - CLL

HMP Education

20:36

Gebroe Family Lecture: Drug-Drug interactions in the era of TKIs

HMP Education

21:09

Minimal residual disease (MRD) in CLL: Is it clinically relevant?

HMP Education

21:38

Risk Assessment in the Era of Novel Agents: What prognostic factors are clinically relevant?

HMP Education

25:09

CLL: Long-term updates on ibrutinib and idelalisib

HMP Education

23:08

Ibrutinib resistance: Is it predictable? What to do?

HMP Education

17:28

Role of PI3K inhibitors in clinical practice: Uses and pitfalls

HMP Education

21:19

Other new molecules in the CLL pipeline: PI3K inhibitors, SYK inhibitors, etc.

HMP Education

24:09

Update on Venetoclax for CLL

HMP Education

23:28

Richter’s syndrome: What are the options?

HMP Education

21:58

Prince Family Lecture: Clonal Evolution in CLL

HMP Education

6:34

Presentation of best CLL abstract

HMP Education

18:25

Update from the IWCLL 2017

HMP Education

13:34

DEBATE: What is the treatment choice for Waldenstrom macroglobulinemia? - Bendamustine

HMP Education